TY - CHAP M1 - Book, Section TI - Scleredema and Scleromyxedema A1 - Weenig, Roger H. A1 - Pittelkow, Mark R. A2 - Kang, Sewon A2 - Amagai, Masayuki A2 - Bruckner, Anna L. A2 - Enk, Alexander H. A2 - Margolis, David J. A2 - McMichael, Amy J. A2 - Orringer, Jeffrey S. PY - 2019 T2 - Fitzpatrick's Dermatology, 9e AB - Skin disorders that are characterized by increased mucin content, excessive collagen deposition, or fibrocyte hyperplasia are designated as mucinoses, sclerosing disorders, or fibrosing disorders, respectively. As the fibrocyte (fibroblast) is the cellular component of their pathogenesis, these conditions are aptly viewed as various forms of “fibropathy.” In some conditions, one fibrocyte product predominates, such as excessive mucin production in pretibial myxedema or collagen deposition in scleroderma. In others conditions there is a combination of excessive mucin and collagen deposition (scleredema) or excessive mucin deposition and fibrocyte hyperplasia (scleromyxedema and nephrogenic systemic fibrosis). Hence, the nosology of some of these conditions does not accurately describe what is observed histopathologically. For example, “fibromyxedema” more accurately depicts the histopathogenesis of scleromyxedema, as scleromyxedema implies a combination of sclerosis and mucinosis, which more accurately describes scleredema. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/05 UR - accessmedicine.mhmedical.com/content.aspx?aid=1161333047 ER -